Pfizer’s TALZENNA plus XTANDI FDA-approved for earlier-stage metastatic prostate cancer
PFE•Pfizer said the FDA approved TALZENNA plus XTANDI for an earlier metastatic prostate cancer treatment setting. Phase 3 TALAPRO-3 data showed a 52% reduction in the risk of progression or death.
1. FDA approval
Pfizer said the FDA approved TALZENNA plus XTANDI for an earlier metastatic prostate cancer treatment setting. Phase 3 TALAPRO-3 data showed a 52% reduction in the risk of progression or death.
